Novo Nordisk has announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the US Food and Drug Administration (FDA) voted 16-0, recommending the approval of IDegLira for the treatment of adults with Type 2 diabetes. IDegLira is a once-daily, single injection fixed combination of insulin degludec (Tresiba) and liraglutide (Victoza) for the treatment of adults with Type 2 diabetes. The recommendation for approval was based on data from clinical trials which involved more than 3,000 adults with type 2 diabetes. “We look forward to working with the FDA as they complete their review,” said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. As yet no date is set for the probable release of this insulin to market in the UK.
This news item first appeared in Desang Diabetes Magazine, our free-to-receive digital journal. We cover diabetes news, diabetes management equipment (diabetes kit) and news about food suitable for a diabetic diet. Go to the top of this page to sign up – we just need your email address.
Menu
